Sirna Therapeutics Announces Public Offering of Common Stock
May 15 2006 - 7:13AM
PR Newswire (US)
SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Sirna Therapeutics,
Inc. (NASDAQ:RNAI) today announced that it has filed a preliminary
prospectus supplement to a shelf registration statement with the
Securities and Exchange Commission relating to a proposed public
offering of 10,000,000 shares of its common stock. 8,000,000 shares
are being sold by Sirna Therapeutics and an aggregate of 2,000,000
shares are being sold by Oxford Bioscience Partners, The Sprout
Group and Venrock Associates in proportion to their current
ownership of Sirna securities. The underwriters will be granted a
30-day option to purchase an aggregate of up to an additional
1,500,000 shares of common stock from Sirna Therapeutics and the
selling stockholders at the public offering price to cover
over-allotments, if any. Sirna Therapeutics will not receive any
proceeds from the sale of common stock by the selling stockholders.
UBS Investment Bank and J.P. Morgan Securities Inc. are acting as
joint bookrunning managers for the offering. CIBC World Markets
Corp., Leerink Swann & Company and Brean Murray, Carret &
Co. are co-managers. This shall not constitute an offer to sell or
the solicitation of an offer to buy, nor shall there be any sale of
these securities in any state in which the offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of that state. Copies of the preliminary
prospectus supplement may be obtained from UBS Investment Bank, 299
Park Avenue, New York, NY 10171, Attn: Prospectus Department, or
from J.P. Morgan Securities Inc., Prospectus Department, 4 Chase
Metrotech Center, CS Level, Brooklyn, NY 11245, telephone
718-242-8003. About Sirna Therapeutics Sirna Therapeutics is a
clinical-stage biotechnology company developing RNAi-based
therapies for serious diseases and conditions, including age-
related macular degeneration, hepatitis B and C, dermatology,
asthma, Huntington's disease, diabetes and respiratory syncytial
virus. Safe Harbor Statement Statements in this press release which
are not strictly historical, including with respect to the
Company's proposed public offering, are "forward-looking"
statements which should be considered as subject to many risks and
uncertainties. You should consider the risk factors identified in
the preliminary prospectus supplement and accompany prospectuses,
and in Sirna's Securities and Exchange Commission filings,
including the Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Greg Weaver, SVP
and Chief Financial Officer, Sirna Therapeutics, Inc., 415-512-7200
Rebecca Galler Robison, Senior Director, Corporate Strategy, Sirna
Therapeutics, Inc., 303-449-6500 DATASOURCE: Sirna Therapeutics,
Inc. CONTACT: Greg Weaver, SVP and Chief Financial Officer,
+1-415-512-7200, or Rebecca Galler Robison, Senior Director,
Corporate Strategy, +1-303-449- 6500, both of Sirna Therapeutics,
Inc. Web site: http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Oct 2023 to Oct 2024